Parvovirus-based vectors for human gene therapy.
It is becoming increasingly clear that the parvovirus-based vectors may prove to be a useful alternative to the more commonly used retroviral vectors in human gene therapy. Specifically, the adeno-associated virus 2 (AAV), a human parvovirus, has gained particular attention in view of its nonpathogenic nature as well as its remarkable site-specificity of integration into the human chromosome. Using the recombinant AAV vector system, it is feasible to obtain high-efficiency transduction of slow- or non-cycling primary hematopoietic stem and progenitor cells, without the need for prestimulation with cytokines, which could potentially lead to differentiation of these cells before transplantation.
Srivastava
A
A
Department of Medicine, Indiana University of School of Medicine, Indianapolis 46202-5120, USA.
D015703:Antigens, CD / Q000032:analysis; D018952:Antigens, CD34; D002454:Cell Differentiation; D002478:Cells, Cultured; D004274:DNA, Recombinant / Q000235:genetics; D004279:DNA, Viral / Q000235:genetics; D000229:Dependovirus / Q000235:genetics* / Q000502:physiology; D004351:Drug Resistance / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006412:Hematopoietic Stem Cells / Q000821:virology; D006801:Humans; D009355:Neomycin / Q000494:pharmacology; D016732:Parvovirus B19, Human / Q000235:genetics*; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000235:genetics; D016662:Virus Integration
D015703:Antigens, CD; D018952:Antigens, CD34; D004274:DNA, Recombinant; D004279:DNA, Viral; D011993:Recombinant Fusion Proteins; D009355:Neomycin